Study Supports Collagen Peptide Product for Joint Health
17 Dec 2013 --- Rousselot has released the results of its latest clinical study investigating the effect of Peptan collagen peptides on knee joint pain and function. Carried out in collaboration with the Shanghai 6th People’s Hospital of Shanghai Jiaotong University in China, the trial reinforces the existing body of scientific evidence demonstrating that Peptan can help to reduce joint pain and improve joint function in patients with osteoarthritis.
The double-blind, placebo-controlled study was carried out on 100 female patients between the ages of 40 and 70 who had been diagnosed with osteoarthritis up to grade III, according to the Kellgren-Lawrence scale. Participants were randomly assigned 8g of Peptan or a placebo per day over six months. Using the WOMAC score to measure joint pain and joint function in daily life, and the Lysholm score to record knee joint function, participants were assessed at three stages throughout the trial: before treatment, at three months and then six months after treatment began. The kidney and liver function of patients were also monitored to document the absence of any side effects.
The results of the study fully confirm the positive effect of a daily intake of Peptan for individuals suffering from osteoarthritis across three key areas:
• The intake of Peptan helps to reduce joint pain: The study confirms the efficacy of Peptan to reduce knee joint pain in osteoarthritis patients, as shown by the results of the WOMAC score. Participants who were given Peptan reported a clear lowering of the WOMAC scores over time and recorded pain scores at the end of the study, which were significantly lower than those in the placebo group.
• The use of Peptan benefits joint function: The efficacy of Peptan in improving knee joint function was also demonstrated by the study. The WOMAC results were supported by the Lysholm score, an assessment specifically adapted for measuring the knee joint functionality. Compared to the placebo group, volunteers who received Peptan recorded significantly increased scores on the Lysholm scale, which evaluates joint function in activity such as limping, stair climbing, walking and jumping.
• Peptan is a safe ingredient with no side effects: The clinical trial found no differences in liver or kidney parameters before and after the study, confirming that an 8g daily intake of Peptan for six months is safe for osteoarthritis patients.
Speaking about the results of the latest clinical trial, Dr. Janne Prawitt, general nutrition manager at Rousselot comments: “We’re pleased to announce the results of another scientific study which supports the clinical benefits of Peptan collagen peptides. As one of the major causes of disability in the developed world, osteoarthritis is a leading source of limited mobility and joint pain for both men and women and its prevalence is set to increase as the population ages. Peptan is a natural active ingredient which can help manufacturers meet the growing demand for functional products and supplements that aid healthy aging and offer proven joint function benefits.”
The study is the latest in a growing bank of scientific data which supports Peptan’s functional health benefits. Extensive research has proven that Peptan can promote bone and joint health as well as muscle regeneration, supporting mobility and acting as an effective bioactive protein in sports nutrition. Clinical studies have also shown Peptan’s ability to rejuvenate skin collagen structure delivering visible anti-aging effects. A high quality protein source, collagen peptides are natural, highly digestible and bioactive ingredients which can be incorporated into a range of exciting formulations.
The full Rousselot/Shanghai 6th People’s Hospital of Shanghai Jiaotong University study will be published in April 2014.
